POAG in Epirus, Greece—Fine Mapping of GLC1C Region
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000014
Summary
Studies of families with glaucoma have helped to identify a number of genetic patterns that are characteristic of the disease. One of these is alterations in the GLC1C gene(s), which may be the predominant cause of POAG in northwestern Greece. Dr. Wirtz and her collaborators in Greece have identified a family in Epirote, Greece in which glaucoma appears to be caused by a mutation in the GLC1C gene. They have also found a large population in Epirus, Greece with POAG. It is hoped that clinical studies of the Epirote family will provide more information on the phenotypic variability associated with mutation(s) in GLC1C. Additional genetic analysis of the Epirus population will allow for more precise genetic mapping of the GLC1C gene, which should help in identifying the gene. These studies, if successful, will provide researchers with more information on the genetics of glaucoma.
Related Grants
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego